• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Oculis Holding AG

    6/5/25 4:38:25 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCS alert in real time by email
    S-8 1 d933644ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 5, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    OCULIS HOLDING AG

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Switzerland   2834   Not Applicable

    (Jurisdiction of Incorporation or

    Organization)

     

    (Primary Standard Industrial Classification

    Code Number)

     

    (I.R.S. Employer

    Identification No.)

    Bahnhofstrasse 20

    CH-6300

    Zug, Switzerland

    Tel.: +41-41-711-3960

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

    Stock Option and Incentive Plan Regulation 2023

    (Full title of the plan)

    Oculis US Inc.

    One Gateway Center

    300 Washington Street, Suite 405

    Newton, MA 02458

    Tel.: +1 (617) 928 5886

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Divakar Gupta

    Katie Kazem

    Cooley LLP

    11951 Freedom Dr

    Suite 1400

    Reston, VA 20194

    Tel: +1 (703) 456 8000

    Fax: +1 (703) 450 8100

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☐
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    Oculis Holding AG, a stock corporation (Aktiengesellschaft) incorporated and existing under the laws of Switzerland (the “Company”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register an additional 4,644,456 ordinary shares issuable under the Company’s Stock Option and Incentive Plan Regulation 2023.

    As used in this Registration Statement, unless the context otherwise requires, references to “we,” “us” and “our” refer to Oculis Holding AG.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The documents containing the information specified in Part I of this Registration Statement will be delivered in accordance with Form S-8 and Rule 428(d) under the Securities Act of 1933, as amended (the “Securities Act”). These documents are not required to be, and are not, filed with Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. The documents containing the information specified in Part I will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    Our ordinary shares are listed on The Nasdaq Stock Market LLC under the ticker symbol “OCS” and on The Nasdaq Iceland Main Market under the ticker symbol “OCS”. Our warrants are listed on The Nasdaq Stock Market LLC under the ticker symbol “OCSAW”.

     

    ITEM 1.

    PLAN INFORMATION

    Not required to be filed with this Registration Statement.

     

    ITEM 2.

    REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION

    Not required to be filed with this Registration Statement.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3.

    INCORPORATION OF DOCUMENTS BY REFERENCE

    The following document(s) filed with the Commission by the Company, pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

    (1) The Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Commission on March 11, 2025;

    (2) The Company’s Reports on Form 6-K, filed with the Commission on March 11, 2025, April  14, 2025 (excluding Exhibit 99.2), May  8, 2025 (excluding Exhibit 99.3), May  9, 2025 and June 5, 2025 (excluding Exhibit 99.1); and

    (3) The description of the Company’s Ordinary Shares contained in the Registrant’s Registration Statement on Form 8-A filed on February 28, 2023, including any amendment or report filed for the purpose of updating such description.

    In addition to the foregoing, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and all reports on Form 6-K, or portions thereof, subsequently filed by the Registrant which state that they are incorporated by reference herein, prior to the filing of a post-effective amendment which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents and reports.

    Any document or any statement contained in a document or report incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a document or a statement contained in any subsequently filed document or report that is also incorporated or deemed to be incorporated by reference herein modifies or supersedes such document or statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Subject to the foregoing, all information appearing in the Registration Statement is qualified in its entirety by the information appearing in the documents incorporated by reference.

     

    ITEM 4.

    DESCRIPTION OF SECURITIES

    Not applicable.

     

    ITEM 5.

    INTERESTS OF NAMED EXPERTS AND COUNSEL

    None.

     

    ITEM 6.

    INDEMNIFICATION OF DIRECTORS AND OFFICERS

    Under Swiss corporate law, an indemnification by the corporation of a director or member of the executive committee in relation to potential personal liability is not effective to the extent the director or member of the executive committee intentionally or negligently violated his or her corporate duties towards the corporation. Furthermore, the general meeting of shareholders may discharge (release) the directors and members of the executive committee from liability for their conduct to the extent the shareholders have knowledge of the relevant facts of a potential claim. Such discharge is effective only with respect to claims of the company and of those shareholders who approved the discharge or who have since acquired their shares in full knowledge of the discharge. Most violations of corporate law are regarded as violations of duties towards the corporation rather than towards the shareholders. In addition, indemnification of other controlling persons is not permitted under Swiss corporate law, including shareholders of the corporation.


    Our Articles of Association provide for indemnification of the existing and former members of the board of directors or the executive committee against liabilities arising in connection with the performance of their duties in such capacity. In addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of his or her duties under the employment agreement with the employer.

    We have entered into indemnification agreements with each of the members of our board of directors and executive officers, the form of which has been filed as an exhibit to our annual report on Form 20-F filed with the Securities and Exchange Commission.

     

    ITEM 7.

    EXEMPTION FROM REGISTRATION CLAIMED

    Not applicable.

     

    ITEM 8.

    EXHIBITS

     

      4.1    Amended and Restated Articles of Association of Oculis Holding AG (incorporated by reference to Exhibit 99.2 to our Report on Form 6-K filed on June 5, 2025).
      5.1*    Opinion of Vischer AG, Swiss counsel to Oculis Holding AG, as to the validity of the Ordinary Shares being registered.
     10.1    Stock Option and Incentive Plan Regulation 2023 of Oculis Holding AG (incorporated by reference to Exhibit 4.7 to our Report on Form 20-F filed on March 11, 2025).
     23.1*    Consent of PricewaterhouseCoopers, SA., independent registered accounting firm for Oculis Holding AG.
     23.2*    Consent of Vischer AG (included as part of Exhibit 5.1).
     24.1*    Power of Attorney (included on the signature page hereto).
    107*    Filing Fee Table.

     

    *

    Filed herewith.

     

    ITEM 9.

    UNDERTAKINGS

    (a) The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

      (ii)

    To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post- effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

      (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;


    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Switzerland, on June 5, 2025.

     

    OCULIS HOLDING AG
    By:   /s/ Riad Sherif
    Name: Riad Sherif
    Title: Chief Executive Officer

    POWER OF ATTORNEY

    Each of the undersigned individuals hereby severally constitutes and appoints each of Riad Sherif and Sylvia Cheung as the attorneys-in-fact for the undersigned, in any and all capacities, with full power of substitution, to sign on such person’s behalf, individually and in each capacity stated below, any and all amendments to this registration statement, and any subsequent registration statement filed by the Registrant pursuant to Rule 462(b) of the Securities Act, and to file or cause to be filed the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and each of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following person in the capacities indicated and on the date indicated below.

     

    Signature

      

    Title

     

    Date

    /s/ Riad Sherif

    Riad Sherif

      

    Chief Executive Officer

    (Principal Executive Officer)

      June 5, 2025

    /s/ Sylvia Cheung

    Sylvia Cheung

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      June 5, 2025

    /s/ Anthony Rosenberg

    Anthony Rosenberg

       Executive Chairman of the Board   June 5, 2025

    /s/ Arshad M. Khanani, M.D.

    Arshad M. Khanani, M.D.

       Director   June 5, 2025

    /s/ Christina Ackermann

    Christina Ackermann

       Director   June 5, 2025

    /s/ Geraldine O’Keeffe

    Geraldine O’Keeffe

       Director   June 5, 2025

    /s/ Lionel Carnot

    Lionel Carnot

       Director   June 5, 2025

    /s/ Martijn Kleijwegt

    Martijn Kleijwegt

       Director   June 5, 2025

    /s/ Robert K. Warner

    Robert K. Warner

       Director   June 5, 2025


    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned has signed this registration statement, solely in the capacity as the duly authorized representative of the Registrant, in Boston, Massachusetts, on June 5, 2025.

     

    OCULIS US INC
    By:   /s/ Sylvia Cheung
    Name: Sylvia Cheung
    Get the next $OCS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCS

    DatePrice TargetRatingAnalyst
    12/5/2023$30.00Buy
    Chardan Capital Markets
    10/5/2023$35.00Buy
    Stifel
    6/14/2023$22.00Buy
    BofA Securities
    6/12/2023$28.00Buy
    H.C. Wainwright
    6/8/2023$58.00Outperform
    Robert W. Baird
    5/10/2023$23.00Buy
    Pareto
    4/28/2023$27.00Outperform
    Wedbush
    More analyst ratings

    $OCS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oculis Publishes Results of 2025 Annual General Meeting

      ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The Company's shareholders approved all agenda items. The shareholders approved the 2024 Annual Report including the 2024 Annual (Statutory) Financial Statements and the 2024 Consolidated Financial Statements. The shareholders acknowledged that on a standalone statutory financial statement basis, the Company incurred a loss of CHF 5,179,000 with respect to the financial year ended December 31, 2024, and

      6/5/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Participate in Upcoming June Investor Conferences

      ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences: Goldman Sachs Annual Healthcare ConferenceJune 9-11; Miami, FL, U.S.Fireside chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET. J.P. Morgan European Healthcare Conference June 12; London, U.K.Riad Sherif, MD, Chief Executive Officer, will be attending. The Company will be available for one-on-one meetings dur

      6/3/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Publishes Invitation to the Annual General Meeting

      ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

      5/9/25 4:05:00 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Leadership Updates

    Live Leadership Updates

    See more
    • Oculis Publishes Invitation to the Annual General Meeting

      ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

      5/9/25 4:05:00 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

      Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Daniel S. Char to the role of Chief Legal Officer, leading Oculis' legal, compliance and corporate governance functions. Mr. Char brings over 35 years of success in global legal leade

      10/2/24 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Financials

    Live finance-specific insights

    See more
    • Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

      DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event

      5/22/23 6:30:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

      ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica

      4/4/23 7:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    SEC Filings

    See more
    • SEC Form S-8 filed by Oculis Holding AG

      S-8 - Oculis Holding AG (0001953530) (Filer)

      6/5/25 4:38:25 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      6/5/25 4:05:17 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      5/9/25 4:10:10 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Oculis Holding AG with a new price target

      Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

      12/5/23 8:03:01 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Oculis Holding AG with a new price target

      Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00

      10/5/23 7:50:21 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Oculis Holding AG with a new price target

      BofA Securities initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $22.00

      6/14/23 8:10:40 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Oculis Holding AG

      SC 13G - Oculis Holding AG (0001953530) (Subject)

      12/9/24 9:43:55 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oculis Holding AG

      SC 13G/A - Oculis Holding AG (0001953530) (Subject)

      11/7/24 4:15:49 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care